Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2022-03-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
马应龙关于续聘2022年度会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's decision to reappoint an accounting firm (audit firm) for the fiscal year 2022. It details the audit firm's background, personnel, independence, audit fees, and the approval process by the board and independent directors. It does not contain any actual audit report, financial statements, or audit results. The document is relatively short (2828 characters) and serves as a formal announcement of the intention to renew the audit engagement, pending shareholder approval. Therefore, it is not the audit report itself but an announcement related to audit services. This fits best under the category of Regulatory Filings (RNS) as it is a regulatory announcement about audit firm appointment rather than the audit report or annual report itself.
2022-03-22 Chinese
马应龙2021年度审计委员会工作报告
Audit Report / Information Classification · 95% confidence The document is titled '2021 年度审计委员会工作报告' which translates to '2021 Annual Audit Committee Work Report'. It references the audit committee's activities, including supervision of external auditors, internal audit guidance, review of financial reports, and evaluation of internal controls for the year 2021. The document is relatively short (1240 characters) and focuses on audit committee work rather than presenting full financial statements or comprehensive financial performance data. It does not contain the full annual report or detailed financial statements but rather a report on audit committee activities and opinions. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and related audit committee work reports. Therefore, the appropriate classification is AR with high confidence. FY 2021
2022-03-22 Chinese
关于马应龙非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Regulatory Filings
2022-03-22 Chinese
马应龙2021年年度报告
Annual Report Classification · 100% confidence The document is titled "2021 年年度报告" which translates to "2021 Annual Report". It is issued by 马应龙药业集团股份有限公司 (Mayinglong Pharmaceutical Group Co., Ltd). The text includes detailed financial data, management discussion and analysis, company information, risk disclosures, and audit opinions. It contains comprehensive financial statements and extensive narrative sections typical of a full annual report. The document length is 15,000 characters, indicating a full report rather than a brief announcement. The presence of an auditor's unqualified opinion and detailed financial metrics further confirms this is the official yearly report covering company activity and full financial performance for the fiscal year 2021. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-03-22 Chinese
马应龙2021年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the 2021 annual report summary of 马应龙药业集团股份有限公司 (Mayinglong Pharmaceutical Group Co., Ltd.). It contains detailed financial data for the year 2021, including revenue, net profit, quarterly financial data, business segments, industry analysis, shareholder information, and management discussion and analysis. The document is comprehensive and exceeds 13,000 characters, indicating it is a full report rather than a brief announcement. It includes audited financial figures and detailed operational and strategic information typical of an Annual Report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-03-22 Chinese
马应龙关于申请银行综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the company's board regarding the application for a comprehensive bank credit facility. It details the proposed credit limits, terms, and authorization for management to use the credit line. There are no financial statements or detailed financial data presented, nor is this a report or presentation. The content clearly relates to financing activities and capital structure updates. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and focused on financing, not a report publication or regulatory filing. Confidence is high due to clear content and context.
2022-03-22 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.